SCHEMBL23830378

SCHEMBL23830378

COc1nc(C)ccc1Cn1nc(C(=O)NCC2(O)CC2)c2ncc(C)cc21

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 1/20 0.41
PDE6D O43924 2/20 0.35
PDE6A P16499 2/20 0.35
PDE6G P18545 2/20 0.35
PDE6B P35913 2/20 0.35
PDE6C P51160 2/20 0.35
PDE6H Q13956 2/20 0.35
P2RX7 Q99572 4/20 0.34
HTR4 Q13639 1/20 0.33
ACSS2 Q9NR19 1/20 0.33
PDCD1 Q15116 1/20 0.33
CD274 Q9NZQ7 1/20 0.33
KLKB1 P03952 1/20 0.33
RORC P51449 7/20 0.33
KCNH2 Q12809 1/20 0.33
CNR2 P34972 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23830377 0.87 CSF1R (0.40) CSF1RP2RX7HTR4PDCD1CD274
SCHEMBL23830367 0.87 PDE6D (0.35) PDE6DPDE6APDE6GPDE6BPDE6C
SCHEMBL23830307 0.85 PDE6D (0.36) PDE6DPDE6APDE6GPDE6BPDE6C
SCHEMBL23830328 0.85 CSF1R (0.38) CSF1RP2RX7PDCD1CD274KLKB1
SCHEMBL23830274 0.84 P2RX7 (0.38) P2RX7ACSS2PDCD1CD274KLKB1
SCHEMBL23830323 0.83 CSF1R (0.44) CSF1RPDE6DPDE6APDE6GPDE6B
SCHEMBL23830354 0.83 SCN9A (0.36) PDE6DPDE6APDE6GPDE6BPDE6C
SCHEMBL23830327 0.82 PDE6D (0.52) PDE6DPDE6APDE6GPDE6BPDE6C
SCHEMBL23830351 0.81 P2RX7 (0.35) P2RX7HTR4ACSS2RORC
SCHEMBL23830363 0.80 CSF1R (0.44) CSF1RPDE6DPDE6APDE6GPDE6B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210292333-A1 CONDENSED AZAHETEROARYL COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY AGAINST TUBERCULOSIS BACTERIA CADILA HEALTHCARE LIMITED (IN) 2021-09-23 US claimed
CN-112543757-A Condensed azaheteroaryl compounds having antibacterial activity against tubercle bacillus 卡迪拉保健有限公司 2021-03-23 CN claimed
US-20210292333-A1 CONDENSED AZAHETEROARYL COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY AGAINST TUBERCULOSIS BACTERIA CADILA HEALTHCARE LIMITED (IN) 2021-09-23 US disclosed
CN-112543757-A Condensed azaheteroaryl compounds having antibacterial activity against tubercle bacillus 卡迪拉保健有限公司 2021-03-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210292333-A1 CONDENSED AZAHETEROARYL COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY AGAINST TUBERCULOSIS BACTERIA DPEP1, SAT1, PEPD CSF1R 532/4885PDE6D 3804/4885PDE6A 1704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.